Mannitolo Bioindustria L.I.M. (Mannitol)

Mannitol increases plasma osmolality when given intravenously, creating an osmotic gradient that draws water from intracellular compartments into the bloodstream. This shift expands intravascular volume, enhances kidney filtration, and reduces cerebral edema by dehydrating brain cells.

The dose of Mannitolo Bioindustria L.I.M. is individualized and set by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Specific dosing regimens are not provided here.

Safety data for mannitol in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is only recommended when the potential benefit outweighs any possible risk to the mother or infant.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mannitol is a sugar‑alcohol osmotic agent that acts quickly when given intravenously. Compared with hypertonic saline, mannitol provides a larger osmotic gradient without adding sodium load, making it preferred for rapid reduction of intracranial pressure, though both agents have specific clinical niches.

Store Mannitolo Bioindustria L.I.M. at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct light and moisture, and avoid freezing to maintain solution stability.

Mannitolo Bioindustria L.I.M. is administered intravenously by a healthcare professional. It is typically given as a sterile solution infused over a controlled period, with dosing and infusion rate determined by the treating physician based on the clinical indication.

Serious risks include acute renal failure, pulmonary edema, severe electrolyte disturbances such as hypernatremia, and rare but life‑threatening allergic reactions or anaphylaxis. Continuous monitoring of renal function, fluid balance and electrolytes is essential during therapy.

Mannitolo Bioindustria L.I.M. should be avoided in patients with known hypersensitivity to mannitol, severe renal impairment, uncontrolled heart failure, active pulmonary edema, or in those where rapid fluid shifts could worsen their condition.